Your browser is no longer supported. Please, upgrade your browser.
LH [NYSE]
Laboratory Corporation of America Holdings
IndexS&P 500 P/E9.52 EPS (ttm)28.17 Insider Own0.10% Shs Outstand96.30M Perf Week-1.37%
Market Cap25.59B Forward P/E14.84 EPS next Y18.07 Insider Trans-4.98% Shs Float95.11M Perf Month-11.22%
Income2.76B PEG- EPS next Q5.75 Inst Own91.70% Short Float1.92% Perf Quarter-4.63%
Sales16.55B P/S1.55 EPS this Y90.00% Inst Trans0.10% Short Ratio2.30 Perf Half Y-5.33%
Book/sh109.29 P/B2.45 EPS next Y-34.45% ROA13.50% Target Price342.57 Perf Year20.76%
Cash/sh21.34 P/C12.56 EPS next 5Y-7.51% ROE27.50% 52W Range212.85 - 317.17 Perf YTD-14.69%
Dividend- P/FCF9.21 EPS past 5Y29.60% ROI12.10% 52W High-15.49% Beta1.07
Dividend %- Quick Ratio1.90 Sales past 5Y10.00% Gross Margin37.20% 52W Low25.93% ATR7.66
Employees72400 Current Ratio2.10 Sales Q/Q4.30% Oper. Margin23.10% RSI (14)31.47 Volatility2.45% 2.53%
OptionableYes Debt/Eq0.52 EPS Q/Q-15.60% Profit Margin16.70% Rel Volume1.14 Prev Close272.15
ShortableYes LT Debt/Eq0.52 EarningsFeb 10 BMO Payout0.00% Avg Volume795.38K Price268.05
Recom1.70 SMA20-7.21% SMA50-7.99% SMA200-5.34% Volume906,568 Change-1.51%
Jan-11-21Upgrade Argus Hold → Buy $245
Jan-11-21Downgrade Wolfe Research Peer Perform → Underperform
Jan-08-21Downgrade Wolfe Research Outperform → Peer Perform
Jul-14-20Upgrade BofA Securities Neutral → Buy $194 → $220
Jul-13-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Resumed Deutsche Bank Buy $210
May-15-20Upgrade Mizuho Neutral → Buy $158 → $186
Apr-29-20Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-27-20Upgrade Wolfe Research Underperform → Peer Perform
Apr-27-20Upgrade Citigroup Neutral → Buy $204 → $214
Jan-08-20Initiated Wells Fargo Overweight $210
Jul-16-19Upgrade BofA/Merrill Underperform → Neutral
Jun-21-19Upgrade Deutsche Bank Hold → Buy $180 → $220
Apr-02-19Upgrade Jefferies Hold → Buy $154 → $190
Jan-17-19Initiated UBS Buy $169
Jan-03-19Downgrade BofA/Merrill Neutral → Underperform
Dec-03-18Downgrade Craig Hallum Buy → Hold
Oct-30-18Downgrade Argus Buy → Hold
Oct-25-18Downgrade Canaccord Genuity Buy → Hold $190 → $162
Oct-19-18Resumed BofA/Merrill Buy
Jan-25-22 11:10AM  
Jan-24-22 10:02AM  
09:53AM  
Jan-21-22 05:50PM  
05:38PM  
09:52AM  
09:27AM  
Jan-20-22 06:00PM  
10:31AM  
08:25AM  
08:22AM  
07:36AM  
07:31AM  
Jan-19-22 01:38PM  
11:52AM  
11:39AM  
11:28AM  
10:57AM  
09:38AM  
Jan-18-22 09:38PM  
08:51AM  
07:19AM  
Jan-17-22 09:25AM  
09:17AM  
08:36AM  
Jan-14-22 05:50PM  
08:29AM  
Jan-13-22 09:34AM  
09:14AM  
06:52AM  
Jan-12-22 10:00AM  
Jan-11-22 06:00PM  
12:10PM  
09:30AM  
09:28AM  
Jan-10-22 04:40PM  
04:32PM  
01:38PM  
10:19AM  
10:17AM  
10:15AM  
10:11AM  
10:08AM  
09:40AM  
06:58AM  
Jan-07-22 11:58AM  
11:23AM  
Jan-06-22 12:03PM  
11:58AM  
09:33AM  
Jan-05-22 05:50PM  
04:24PM  
11:35AM  
11:07AM  
10:30AM  
09:35AM  
07:59AM  
Jan-04-22 04:29PM  
09:46AM  
07:42AM  
Jan-03-22 10:30AM  
10:05AM  
09:15AM  
Dec-31-21 10:05AM  
Dec-30-21 11:07AM  
Dec-29-21 11:05AM  
Dec-28-21 10:04AM  
02:38AM  
Dec-27-21 11:20AM  
11:07AM  
10:37AM  
09:40AM  
09:40AM  
Dec-24-21 11:40AM  
11:31AM  
08:10AM  
07:40AM  
Dec-23-21 01:35PM  
10:46AM  
10:26AM  
09:05AM  
07:09AM  
Dec-22-21 06:10PM  
11:08AM  
11:01AM  
09:54AM  
07:56AM  
Dec-21-21 12:22PM  
10:17AM  
08:05AM  
Dec-20-21 10:57AM  
09:00AM  
09:00AM  
Dec-17-21 03:00PM  
07:58AM  
Dec-16-21 02:41PM  
07:41AM  
07:30AM  
Dec-15-21 01:55PM  
12:00PM  
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company has a collaboration agreement with community clinical oncology research network, LLC to understand the impact of disparities in precision medicine for people with cancer; and strategic collaboration with GeneCentric Therapeutics, Inc. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gilliland Dwight GaryDirectorDec 15Sale302.26500151,1286,252Dec 17 10:36 AM
van der Vaart Sandra DEVP, Chief Legal OfficerSep 15Option Exercise84.864,500381,8709,765Sep 17 12:20 PM
van der Vaart Sandra DEVP, Chief Legal OfficerSep 15Sale296.784,5001,335,5105,265Sep 17 12:20 PM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 07Option Exercise84.864,500381,8709,737Jun 09 02:03 PM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 07Sale266.564,5001,199,5205,237Jun 09 02:03 PM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 06Sale276.552,500691,3757,844May 10 08:21 AM
BELINGARD JEAN-LUCDirectorMay 03Option Exercise98.492,600256,07418,169May 05 10:48 AM
BELINGARD JEAN-LUCDirectorMay 03Sale269.162,600699,80315,569May 05 10:48 AM
van der Vaart Sandra DEVP, Chief Legal OfficerMar 30Sale251.88812204,5275,237Apr 01 08:32 AM
Schroeder Mark SEVP, President-Diagnostics LabMar 30Sale251.88667168,0045,006Apr 01 08:32 AM
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 18Option Exercise157.092,166340,2512,660Feb 19 02:17 PM
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 18Sale241.512,317559,589343Feb 19 02:17 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 16Sale236.5520849,2024,426Feb 17 04:28 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 16Sale237.0618844,5674,339Feb 17 04:27 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 05Sale225.8510924,6184,219Feb 08 03:43 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 05Sale225.8520345,8484,152Feb 08 03:40 PM
Williams R SandersDirectorJan 26Option Exercise98.491,300128,0375,246Jan 28 12:11 PM